Osteoporosis Management in a Glucocorticoid-Treated Patient
A 67-year-old postmenopausal woman with polymyalgia rheumatica has been on prednisone for 5 months: 20 mg daily for 8 weeks, now tapering and currently at 7.5 mg daily, with a planned 12–18 month course. She has a prior low-trauma distal radius fracture at age 60. DXA: femoral neck T-score −2.3, lumbar spine T-score −2.6. FRAX (with glucocorticoid adjustment) gives a 10-year major osteoporotic fracture risk of 24% and hip fracture risk of 4.5%. Labs: calcium, 25-OH vitamin D 22 ng/mL, creatinine, and PTH normal; she is euvolemic. She takes calcium 600 mg twice daily but no other bone agents.
1. What pharmacologic therapy should she receive, and how do glucocorticoid dose and duration factor into the decision?
Read the worked answer
She meets criteria for pharmacologic therapy: prior fragility fracture, T-score ≤ −2.5 at the spine, and a glucocorticoid exposure (≥7.5 mg/day for ≥3 months) that independently raises fracture risk. Guidelines (ACR) recommend an oral bisphosphonate (alendronate or risedronate) as first-line for most glucocorticoid-treated patients at high risk, with anabolic therapy (teriparatide, abaloparatide, or romosozumab) reserved for very high risk (e.g., multiple fractures, very low T-score, recent fracture). Given her prior fracture and T-score, an oral bisphosphonate is appropriate; consider anabolic therapy if she has another fracture or if risk is judged very high. Key points: do not wait for the steroid course to end - bone loss is fastest in the first 3–6 months; ensure vitamin D repletion (she is at 22 ng/mL - supplement to ≥30), adequate calcium intake (diet + supplement to ~1,000–1,200 mg/day), weight-bearing exercise, fall prevention, and use the lowest effective prednisone dose with the shortest duration. Recheck DXA in 1–2 years.
2. She asks whether she can stop the bone medication once prednisone is discontinued, and whether her vitamin D level needs correction before starting. How do you counsel her?
Read the worked answer
Counsel that fracture risk persists after stopping glucocorticoids - bone density does not fully recover, and the benefit of treatment extends beyond the steroid course, so she should continue the bisphosphonate (typically 3–5 years, reassessed with DXA and clinical risk). Do not stop it simply because prednisone ends. On vitamin D: correct the deficiency (22 ng/mL) with supplementation to ≥30 ng/mL, but this does not require delaying bisphosphonate initiation - repletion can proceed concurrently. Reinforce adherence, since oral bisphosphonates require correct administration (morning, upright, 30 min before food, full glass of water) and dental review before starting. Reassess fracture risk periodically, and if she has another fracture on therapy, reconsider anabolic therapy. Coordinate tapering of prednisone with the rheumatology plan.